According to the research from Frost & Sullivan, the obese population in China has increased from 180 million in 2016 to 230 million in 2021, and would reach 270 million by 2025. With the vigorous development of the beauty economy, the refinement of life and aesthetic concepts, and the introduction of non-surgical medical aesthetic techniques (like Energy-based procedures and injection procedures etc.), the market hotspots in lipolytic and shaping is continuing to rise.

Injection lipolytic market in China is in its early stages, and no products have been approved by NMPA yet while some local companies are developing this product line. Based on the report of Frost & Sullivan, the injection lipolytic market in China will reach 1.2 billion RMB in 2026 with the listing of NMPA’s approval products and the increasing demand of lipolytic medical aesthetic in the future.

BTM 101 is the first product of BTM to following its development strategy to enter into the field of Medical Aesthetic, and BTM will continue to introduce innovative drugs & medical device in Medical Aesthetic.